论文部分内容阅读
[目的]分析肝细胞癌(HCC)中5q13.2和8p23.1位点的杂合性缺失(LOH)情况,以探索新的抑癌基因。[方法]应用聚合酶链反应—非变性聚丙烯酰胺凝胶电泳法对83例HCC患者基因组DNA中的5q13.2和8p23.1位点的LOH进行检测,并将其与临床参数进行关联分析。[结果]83例HCC患者基因组中,36.1%(30例)存在5q13.2位点LOH,在该位点存在OCLN、SMN2、SERF1A、SMN1、NAIP和GTF2H2基因;8p23.1的D8S503和D8S1130位点分别存在68.4%和61.3%的LOH。[结论]HCC患者基因组中存在较高频率的5q13.2和8p23.1位点LOH,这些位点中可能存在与HCC发生密切相关的基因。
[Objective] To analyze the loss of heterozygosity (LOH) at 5q13.2 and 8p23.1 in hepatocellular carcinoma (HCC) to explore novel tumor suppressor genes. [Method] Polymerase chain reaction-non-denaturing polyacrylamide gel electrophoresis was used to detect the LOH of 5q13.2 and 8p23.1 loci in 83 cases of HCC patients and to correlate them with clinical parameters . [Results] There were 5q13.2 LOH loci in 36.1% (30 cases) of 83 HCC patients and OCLN, SMN2, SERF1A, SMN1, NAIP and GTF2H2 genes in this locus; D8S503 and D8S1130 There were 68.4% and 61.3% LOH, respectively. [Conclusion] There are higher frequencies of LOH at 5q13.2 and 8p23.1 loci in HCC patients, and there may be genes closely related to HCC in these loci.